Objective To explore the clinical value of modified HOOD technique in laparoscopic radical prostatectomy.Methods A retrospective analysis was conducted on the perioperative data of 71 patients who underwent laparoscopic radical prostatectomy performed by the same surgical team during Jul.20,2022 and Dec.20,2024.The patients were divided into the observation group(n=28,modified HOOD resection)and conventional group(n=43,conventional resection).Results The observation group had better urinary continence,with higher immediate continence rate(20％vs.9.3％),shorter drainage tube removal time[4(3-6)d vs.6(3-9)d]and shorter hospital stay[6.5(4-13)d vs.9(5-11)d]compared with the conventional group.There were no statistically significant differences in operation time,intraoperative blood loss,and postoperative pathological staging between the two groups(P＞0.05).Conclusion The modified HOOD technique is safe and feasible in laparoscopic radical prostatectomy,which can effectively improve postoperative urinary continence,promote recovery,and enhance patients'quality of life.

Objective To explore the clinical value of modified HOOD technique in laparoscopic radical prostatectomy.Methods A retrospective analysis was conducted on the perioperative data of 71 patients who underwent laparoscopic radical prostatectomy performed by the same surgical team during Jul.20,2022 and Dec.20,2024.The patients were divided into the observation group(n=28,modified HOOD resection)and conventional group(n=43,conventional resection).Results The observation group had better urinary continence,with higher immediate continence rate(20％vs.9.3％),shorter drainage tube removal time[4(3-6)d vs.6(3-9)d]and shorter hospital stay[6.5(4-13)d vs.9(5-11)d]compared with the conventional group.There were no statistically significant differences in operation time,intraoperative blood loss,and postoperative pathological staging between the two groups(P＞0.05).Conclusion The modified HOOD technique is safe and feasible in laparoscopic radical prostatectomy,which can effectively improve postoperative urinary continence,promote recovery,and enhance patients'quality of life.

Objective:To examine the characteristics of blood lipid profile and the correlation with clinic-pathological features of pancreatic cancer patients.Methods:The clinical and pathological data of 265 pancreatic cancer patients who received radical surgical treatment at Department of General Surgery,Qilu Hospital,Shandong University from January 2013 to September 2020 were collected and analyzed retrospectively. Among the 265 pancreatic cancer patients,there were 170 males and 95 females,with age of (61.0±9.6)years(range:28 to 86 years). General information,lipid indicators and clinic-pathological information were collected from electronic medical record system,and follow-up information gained by telephone. According to level of serum lipid in pancreatic cancer patients,265 patients were divided into dyslipidemia group( n=115) and normal lipid group( n=150). Pearson χ 2,Student′s t tests, variance analysis or univariate Logistic regression was used to analyze the correlation between dyslipidemia and clinico-pathological characteristics of pancreatic cancer,respectively. Kaplan-Meier survival curve was used to assessed the influence of dyslipidemia on prognosis of pancreatic cancer patients. Results:In 265 pancreatic cancer patients,115(43.4%)of them had dyslipidemias,and the most common form was increase of triglyceride(TG)(72.2%). In pancreatic cancer with dyslipidemias group,patients with body mass index ≥25 kg/m 2 had higher proportion than normal lipid group(36.1%(26/72) vs. 21.2%(21/99),χ2=4.643, P=0.031); The proportion of carcinoma located at head of pancreas(83.5%(96/115) vs. 40.7%(61/150),χ2=49.412, P<0.01), staging of T1/T2(79.1%(91/115) vs. 60.7%(91/150),χ2=10.316, P<0.01) and lymphatic metastasis(36.5%(42/115) vs. 22.7%(34/150),χ2=6.007, P<0.01) were higher. In patients of pancreatic cancer, dyslipidemias were closely associated with tumor location( OR=10.529, P<0.01)and body mass index( OR=3.671, P=0.008). Serum lipid profile results showed that TG,total cholesterol and high-density lipoprotein(HDL) disorders were associated with tumor location( P<0.05). TG disorder had association with body mass index( P<0.05), and HDL disorder had association with tumor stage( P<0.05). Moreover, the result of survival analysis showed that dyslipidemia was not a factor to impact the prognosis of pancreatic cancer patients underwent surgery( P>0.05). Conclusions:In pancreatic cancer patients,TG disorder was the most common type of dyslipidemia. Dyslipidemia has closely association with clinicopathologic features,including tumor location,body mass index,tumor stage. However,dyslipidemia had little effect on prognosis of pancreatic cancer patients.

Objective:To examine the characteristics of blood lipid profile and the correlation with clinic-pathological features of pancreatic cancer patients.Methods:The clinical and pathological data of 265 pancreatic cancer patients who received radical surgical treatment at Department of General Surgery,Qilu Hospital,Shandong University from January 2013 to September 2020 were collected and analyzed retrospectively. Among the 265 pancreatic cancer patients,there were 170 males and 95 females,with age of (61.0±9.6)years(range:28 to 86 years). General information,lipid indicators and clinic-pathological information were collected from electronic medical record system,and follow-up information gained by telephone. According to level of serum lipid in pancreatic cancer patients,265 patients were divided into dyslipidemia group( n=115) and normal lipid group( n=150). Pearson χ 2,Student′s t tests, variance analysis or univariate Logistic regression was used to analyze the correlation between dyslipidemia and clinico-pathological characteristics of pancreatic cancer,respectively. Kaplan-Meier survival curve was used to assessed the influence of dyslipidemia on prognosis of pancreatic cancer patients. Results:In 265 pancreatic cancer patients,115(43.4%)of them had dyslipidemias,and the most common form was increase of triglyceride(TG)(72.2%). In pancreatic cancer with dyslipidemias group,patients with body mass index ≥25 kg/m 2 had higher proportion than normal lipid group(36.1%(26/72) vs. 21.2%(21/99),χ2=4.643, P=0.031); The proportion of carcinoma located at head of pancreas(83.5%(96/115) vs. 40.7%(61/150),χ2=49.412, P<0.01), staging of T1/T2(79.1%(91/115) vs. 60.7%(91/150),χ2=10.316, P<0.01) and lymphatic metastasis(36.5%(42/115) vs. 22.7%(34/150),χ2=6.007, P<0.01) were higher. In patients of pancreatic cancer, dyslipidemias were closely associated with tumor location( OR=10.529, P<0.01)and body mass index( OR=3.671, P=0.008). Serum lipid profile results showed that TG,total cholesterol and high-density lipoprotein(HDL) disorders were associated with tumor location( P<0.05). TG disorder had association with body mass index( P<0.05), and HDL disorder had association with tumor stage( P<0.05). Moreover, the result of survival analysis showed that dyslipidemia was not a factor to impact the prognosis of pancreatic cancer patients underwent surgery( P>0.05). Conclusions:In pancreatic cancer patients,TG disorder was the most common type of dyslipidemia. Dyslipidemia has closely association with clinicopathologic features,including tumor location,body mass index,tumor stage. However,dyslipidemia had little effect on prognosis of pancreatic cancer patients.

Liver is the most common metastatic site for colorectal cancer (CRC), there is no satisfied approach to treat CRC liver metastasis (CRCLM). Here, we investigated the role of a polycomb protein BMI-1 in CRCLM. Immunohistochemical analysis showed that BMI-1 expression in liver metastases was upregulated and associated with T4 stage, invasion depth and right-sided primary tumor. Knockdown

A 66-year-old male urothelial carcinoma patient with liver and lymph node metastasis received an IV infusion of paclitaxel for injection (albumin bound) 400 mg on day 1 and tegafur, gimeracil and oteracil potassium capsules 50 mg orally twice daily on day 1 to day 14, the interval was 1 week, and each cycle was 21 days. A total of 9 cycles of chemotherapy were performed. The patient complained of priapism occurring about 15 hours (about 1: 00 of the next morning) after intravenous infusion of paclitaxel (albumin bound) in the cycles 1-5 and 7-9, which could disappear about 2 hours later. No special treatment was given. After that, paclitaxel for injection (albumin bound) was not used, and the patient did not have the above symptoms again after changing to immunotherapy as disease progresses. It was considered that the patient′s priapism might be related to paclitaxel for injection (albumin bound).

A 66-year-old male urothelial carcinoma patient with liver and lymph node metastasis received an IV infusion of paclitaxel for injection (albumin bound) 400 mg on day 1 and tegafur, gimeracil and oteracil potassium capsules 50 mg orally twice daily on day 1 to day 14, the interval was 1 week, and each cycle was 21 days. A total of 9 cycles of chemotherapy were performed. The patient complained of priapism occurring about 15 hours (about 1: 00 of the next morning) after intravenous infusion of paclitaxel (albumin bound) in the cycles 1-5 and 7-9, which could disappear about 2 hours later. No special treatment was given. After that, paclitaxel for injection (albumin bound) was not used, and the patient did not have the above symptoms again after changing to immunotherapy as disease progresses. It was considered that the patient′s priapism might be related to paclitaxel for injection (albumin bound).

Isolated cortical vein thrombosis (ICoVT) is very rare and its clinical symptoms lack specificity.Unlike cerebral venous sinus thrombosis,ICoVT rarely presents increased intracranial pressure and optic disc edema.Imaging examination,especially MRI examination,is very important for the diagnosis of this disease.T2 *-weighted gradient echo sequence and susceptibility-weighted imaging contribute to the early diagnosis of the disease.This article reviews the clinical symptoms,diagnosis,and treatment of ICoVT.

OBJECTIVE： To mine the data of azathioprine related death events based on FDA Adverse Event Report System （FAERS）， and to provide reference safe use of azathioprine in clinic. METHODS： Totally 60 quarters of FARES data were downloaded from 2004Q1 to 2018Q4. After drug names standardized by Medex_UIMA_1.3.7 and adverse events classified by MedDRA， death events related to azathioprine were extracted. The safety signals were detected by using ROR and PRR methods. The death events related to azathioprine were analyzed in respects of patient’s general information， reporter’s information， time and country distribution of reports， signal detection results， dose and drug combination of direct and indirect death， reported frequency of indirect deaths. RESULTS： A total of 39 695 azathioprine related death events were gathered， including 707 direct death reports and 3 219 indirect death reports. The media age was 55 years in dead. Physicians and other health professionals reports took up 77.38％. Azathioprine administered orally took up 90.40％ （647/715） in reported cases of known route of adiministration. “Fetal death” （ROR＝4.16， PRR＝4.16） and “neonatal death” （ROR＝4.99， PRR＝4.99） were detected as signal. About 30 percent of the death reports were the old patients. There were cases using azathioprine beyond contraindications or maximum dosage. Among drug combination， immunosuppressive drugs were used most frequently. Infection events were reported most frequently in indirect deaths （3 122 reports）. CONCLUSIONS： The potential death risk of azathioprine should be paid attention to， and the contraindications and dosage of azathioprine should be strictly controlled. Great importance should be paid attention to medication for special population of the elderly and children. It is suggested that genetic testing and precise drug use should be perfected before using azathioprine.

OBJECTIVE:To evaluate the cost-effectiveness of SOX regimen(tegafur+oxaliplatin)vs. CapeOX regimen (capecitabine+oxaliplatin)in the treatment of metastatic colorectal cancer,and to provide reference for exploring more economical first-line regimen of metastatic colorectal cancer. METHODS:Based on published high-quality Ⅲ-phase randomized controlled trial,Markov model was established according to the process of disease development in patients with metastatic colorectal cancer. The model was divided into progression-free survival state,progressive disease state and death state. Combined with relevant data of our hospital,pharmacoeconomic cost-effectiveness analysis was conducted for SOX regimen and CapeOX regimen. Sensitivity analysis validation model was used to analyze the stability of the model. RESULTS:According to the results of Markov model operation,compared to standard CapeOX regimen,SOX regimen could increase 0.14 QALYs,and cost increased by 35 493.45 yuan;incremental cost-effectiveness ratio was 253 524.64 yuan/QALYs,which was higher than willingness-to-pay(WTP) threshold(168 201.201 yuan/QALYs). Single factor sensitivity analysis showed that cost of oxaliplatin had the most important impact on the result of cost-effectiveness analysis. Probabilistic sensitivity analysis depicted that with the increase of GDP per capita,the probability of SOX regimen with cost-effectiveness would increase. CONCLUSIONS:At present,compared with standard CapeOX regimen,SOX regimen has no cost-effectiveness for metastatic colorectal cancer,which is not recommended as the first choice for first-line treatment of metastatic colorectal cancer.